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Abstract
Background: Pain after major lower limb amputation for peripheral arterial disease (PAD) is a significant problem. A
perineural catheter (PNC) can be placed adjacent to the major nerve at the time of amputation with a continuous
local anaesthetic infusion given postoperatively to try and reduce pain. Although low-quality observational data
suggest that PNC usage reduces postoperative opioid requirements, there are limited data regarding its effect on
pain. The aim of PLACEMENT is to explore the feasibility of running an effectiveness trial to assess the impact of a
PNC with continuous local anaesthetic infusion, inserted at the time of amputation, on short and medium-term
postoperative outcomes.
Methods/design: Fifty patients undergoing a major lower limb amputation (below or above the knee) for PAD will
be recruited from two centres. Patients will be randomised in a 1:1 ratio to receive standard postoperative analgesia,
with or without insertion of a PNC and local anaesthetic infusion for the first 5 postoperative days. Outcome data will
be captured for the first 5 days, including pain scores (primary outcome, captured three times a day), opioid use, nausea
or vomiting, itching, dizziness and complications. Patients will be contacted 2 and 6 months after surgery to assess quality
of life, phantom limb pain, chronic stump pain and total healthcare costs. Semi-structured interviews will be conducted
with at least 10 patients (dependent on saturation of analytic themes on preliminary coding) purposefully sampled to
achieve variation in site and study arm. Interviews will explore patients’ perception of post-amputation pain and
its treatment, and experience of study processes. Semi-structured interviews with 5–10 health professionals will
explore feasibility, fidelity, and acceptability of the study. Data from this pilot will be used to assess feasibility of,
and estimate parameters to calculate the sample size for an effectiveness trial. Full ethical approval has been granted
(Wales Research Ethics Committee 3 reference number 16/WA/0353).
Discussion: PLACEMENT will be the first study to explore the feasibility of running an effectiveness trial on PNC usage
for postoperative pain in amputees, and provide parameters to calculate the appropriate sample size for this study.
Trial registration: ISRCTN.com, ISRCTN85710690. Registered on 21 October 2016.
European Clinical Trials Database (EudraCT), 2016-003544-37. Registered on 24 August 2016.
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Background
Peripheral arterial disease (PAD) affects approximately
20% of people aged over 55 years, of whom 1–2% will
eventually require a lower limb amputation [1, 2]. The
management of postoperative pain in this population is
essential for these patients’ short-term recovery and on-
going rehabilitation. Amputees suffer with different types
of pain: immediate postoperative pain, chronic stump pain
(CSP) and phantom limb pain (PLP). Despite numerous
studies, determining how to best manage such patients to
reduce both acute and chronic pain is not clear [3].
Immediate postoperative pain management commonly
involves epidural or intravenous patient controlled anal-
gesia, reliant upon opioid-based agents. The recent UK-
wide National Confidential Enquiry into Patient Out-
come and Deaths (NCEPOD) review into lower limb
amputations found that strong opioids were the most
frequently used type of analgesia postoperatively [4].
Whilst providing excellent pain relief, opioids have many
side effects including nausea, vomiting [5], constipation
[6], sedation and pruritis [7]. Tolerance, dependence and
addiction can occur with prolonged use. Opioid-related
side effects are problematic; they increase in-hospital
costs by 7–16% and length of stay by around 10% [8, 9].
Given the marked side effects of opioids, the American
Society of Anesthesiologists suggests using multimodal
analgesic strategies for managing postoperative pain
[10], which includes utilising peripheral wound catheters
(PWCs) with local anaesthetic infusion where possible.
PWCs are thin catheters placed within the surgical
wound. Perineural catheters (PNCs) are a specific type
of PWC placed adjacent to major nerves, which allow a
continuous infusion of local anaesthetic directly to the
perineural (juxta-neural) space [11]. PWCs can be placed
under direct vision at the time of surgery by the operat-
ing surgeon (surgical PWCs), or percutaneously under
radiological guidance either preoperatively or postopera-
tively (radiological PWCs). In large meta-analyses, PWC
usage is associated with reduced postoperative pain
scores at rest and on movement, opioid usage, nausea
and vomiting, length of hospital stay and increased
patient satisfaction [12], with minimal risk [13, 14].
Use of PNCs for major amputations, inserted adjacent
to either the sciatic nerve (for above-knee amputations
(AKAs)) or the tibial nerve (for below-knee amputations
(BKAs)), was first described in 1991 [15]. A recent sys-
tematic review of PNC use in lower limb amputation
identified seven reports of studies comprising 416
patients [16]. Two were prospective randomised con-
trolled trials (RCTs) [17, 18] whilst the remainder were
observational studies. On meta-analysis, opioid use was
less with the PNC compared to controls (standardised
mean difference -0.59, 95% confidence interval (CI)
-1.10 to -0.07; p = 0.03) [16]. Only two papers provided
data on postoperative pain, with no difference being
demonstrated, although numbers of patients included
were low and comparison groups were non-
standardised. There was no effect on mortality, CSP or
PLP. Importantly, no trials had adequate power to detect
a difference in postoperative pain. A number of other
papers not included in the meta-analysis have suggested
that PNCs reduce postoperative pain [19–22].
Pain after amputation is a significant problem for pa-
tients. The recent 2014 NCEPOD report of lower limb
amputations suggested only 37.5% of patients receive
“good” pain control postoperatively. Postoperative pain
has been shown to be one of the vital factors in patients’
overall satisfaction with their operative experience [23].
The use of a PNC may reduce both postoperative pain
and opioid use, and therefore also opioid side effects
such as nausea, vomiting, constipation and delirium. In
the absence of robust data, a contemporaneous RCT is
necessary to confirm or refute its value in amputees, in
terms of pain relief, opioid use, quality of life (QoL) and
overall cost. The PLACEMENT study aims to recruit 50
patients undergoing major lower limb amputation for
PAD, and assess the feasibility of randomising them in a
1:1 ratio to receive a PNC with a continuous local anaes-
thetic infusion for up to 5 days, inserted at the time of
amputation, or not. Both groups will receive persona-
lised anaesthetic and postoperative analgesic regimes.
While the primary objective is the assessment of feasibil-
ity, it is also necessary to define effectiveness outcomes,
as the unexpected detection of a significant deleterious
effect would be a strong reason not to proceed with an
effectiveness trial. The primary effectiveness outcome
will be short-term pain, with secondary effectiveness
outcomes including opioid use, opioid side effects, long-
term pain, QoL and a cost analysis. A full effectiveness
trial will be deemed appropriate following careful evalu-
ation of the pilot study against published criteria, if at
least 25% of eligible patients are enrolled, and as long as
a minimum of 60% of patients provide primary outcome
data. This protocol has been developed in line with the
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) 2013 statement [24] Additional file 1.
Methods/design
Objectives
The primary objective of PLACEMENT is to assess the
feasibility of running an effectiveness trial to determine
whether the use of a PNC with local anaesthetic infusion
reduces pain in the first 5 postoperative days in ampu-
tees. Key parameters permitting progression to an effect-
iveness trial include effective study design and
management, according to the Acceptance Checklist for
Clinical Effectiveness Pilot Trials (ACCEPT) criteria
[25], described in detail later, the Trial Steering
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Committee (TSC) and Trial Management Group (TMG)
must approve the study as safe, without excessive com-
plications in either study arm, the percentage of eligible
patients that are randomised must be greater than 25%,
and the percentage of randomised patients that provide
data for the primary outcome must be greater than 60%.
Secondary objectives include: to estimate an effect size
(to allow the appropriate sample size to be calculated for
a future RCT); identify barriers to patient recruitment
and site set up; identify the proportion of eligible partici-
pants who consent to the study; identify the proportion
of consented participants who supply primary outcome
data; identify what frequency of pain score measure-
ments, and using which tool, are most suited to identify
pain in this cohort of patients; identify the proportion of
patients reaching follow up to evaluate PLP and CSP
levels; identify which secondary outcomes are important
to include, and how best to assess them; develop a
greater understanding of overall patient experience relat-
ing to pain, and pain management, following a major
amputation; explore the feasibility of blinding the surgi-
cal and anaesthetic teams to study allocation preopera-
tively; and develop a suitable framework for a full health
economic evaluation in a future RCT.
In parallel with this work, we are also undertaking
research to identify the most important outcomes (core
outcome sets) for future amputation research. A proto-
col for this work is reported separately [26].
Design
PLACEMENT is a pragmatic randomised non-blinded
1:1 pilot study. In the UK, it is classified as a clinical trial
of an investigational medical product (CTIMP) type A,
as both arms use procedures and medications that are
already used in routine clinical practice.
Participants
Fifty participants will be enrolled over 12 months.
Adults undergoing major lower limb amputation, either
BKA (trans-tibial) or AKA (trans-femoral), for complica-
tions of PAD are considered. Patients with PAD were
considered the most suitable for this study as in the UK
PAD is the most common reason for a patient requiring
an amputation [27], and other less common indications,
particularly trauma, are associated with extremes of
phantom limb pain [28]. The pharmacokinetics of opi-
oids are altered with increasing age, deteriorating renal
function and polypharmacy, attributes commonly
encountered in patients with PAD but far less common
in patients having amputations for other reasons, leading
to unpredictable adverse drug effects and interactions
[29]. Finally, the NCEPOD can provide clear data on
recent UK amputation practice [4], providing motivation
for this study.
Inclusion criteria
The following patients will be suitable for inclusion in
the study: patients aged 18 years or older, undergoing
elective or emergency major lower limb amputation
(BKA, or AKA) for complications of PAD, able to assess
pain using a verbal rating scale (VRS) and with a life
expectancy longer than 2 weeks. For women of child-
bearing potential, they need to be willing to undergo a
pregnancy test before the study and agree to either use a
highly effective method of contraception or abstain from
sexual intercourse until at least 7 days after their
amputation.
Exclusion criteria
The following patients will be excluded from enrolling
in the study: patients undergoing digital, metatarsal or
tarsal amputation, disarticulation of the hip or hindquar-
ter amputation, simultaneous bilateral amputations or
through-knee amputation. Patients who are unable to
provide consent due to incapacity (as defined by the
Mental Capacity Act 2005) will be excluded, as will
vulnerable or protected adults, and pregnant females.
Patients with an allergy or intolerance to any of the
substances in the PNC, or local anaesthetic agents, or
chronically taking class IB anti-arrhythmic agents or
local anaesthetic agents, for example in the form of
transdermal patches, will be excluded, as will patients
expected to be managed in the intensive care unit post-
operatively and be sedated for more than 24 hours. Pa-
tients undergoing a subsequent amputation who have
already been enrolled to participate in the PLACEMENT
study will not be recruited again.
Patients who meet the inclusion criteria but who sub-
sequently are not suitable include patients in whom a
planned major amputation was not performed (due to
either anaesthetic or surgical difficulties), patients in
whom a major amputation was performed but the
appropriate nerve was not identified, patients who, due
to instability in the intra-operative period, require
admission to the intensive care unit postoperatively and
are most likely to be sedated for more than 24 hours,
and patients who, due to instability in the intra-
operative period, are not expected to survive more than
2 weeks.
Trial interventions
Intervention arm
Participants randomised to the active treatment arm re-
ceive usual care with levobupivacaine hydrochloride
0.125% delivered to the perineural space via a PNC placed
at the time of the amputation, at a dose of 2.5–15 mg/h,
continued for up to 5 days. All participating surgeons will
be assessed and trained prior to study enrolment to en-
sure PNC placement is standardised across the two
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sites. Local anaesthetic infusion will be via an elasto-
meric pump, with standard monitoring of the pump
during the period of its use.
For PNC placement, the sciatic nerve (for AKA) or
tibial nerve (for BKA) is identified. The nerve is trans-
ected sharply under gentle tension, to allow the cut end
of the nerve to retract from the wound to reduce neur-
oma formation [30]. An epidural catheter (20G,
0.85 mm diameter) is used as the PNC, and placed in
the perineural space under direct vision after the limb
has been removed. A non-coring Tuohy needle is first
placed in the perineural space, the fenestrated end of the
epidural catheter advanced along the needle so to lie ad-
jacent to the nerve, approximately 10–20 cm cranial
from the cut end, and the needle withdrawn leaving the
catheter in place. A suitable exit site for the catheter on
the lateral aspect of the amputation stump is selected,
and the Tuohy needle passed through the skin (external
to internal) at this point. The free end of the epidural
catheter is then passed through the needle, which is then
withdrawn to leave the catheter exiting the wound. The
amputation is completed and the epidural catheter is
coiled and secured under an adhesive dressing. No op-
erative blockade of the femoral nerve (for AKA) or
peroneal nerve (for BKA) will be performed routinely.
Control arm
Participants randomised to the control arm receive usual
care (standard anaesthetic and postoperative analgesia
alone). The primary mode of anaesthetic (general, epi-
dural, spinal, regional) will be recorded. Regional nerve
blocks or PNCs, placed either during the anaesthetic
phase or preoperatively, are permitted in either arm.
Their use will be recorded, and if a PNC is placed, the
duration of postoperative local aesthetic infusion will be
recorded. In the instance of a preoperative PNC and a
study PNC being placed in the same patient, the local
anaesthetic infusion rate will be carefully checked to
ensure local anaesthetic toxicity will not occur.
Postoperative analgesia will be determined by the
anaesthetic and surgical team, tailored to the patients’
individual needs. As standard, all patients will receive
regular paracetamol. Opioids are also prescribed as
required, and are given either intravenously via a
patient-controlled analgesia device, or orally by the ward
nurses. Gabapentinoids or tricyclic antidepressants are
used for neuropathic or phantom limb pain. Other
analgesic adjuncts such as ketamine infusions are also
permitted. Use of all analgesics will be recorded in both
intervention and control arms.
Outcomes
While this is primarily a pilot study, and as such the
feasibility objectives listed above are the primary
measures of importance, we feel it valuable to also define
putative effectiveness outcomes. Depending upon the
study results these may, or may not, carry over into a
future effectiveness trial.
Primary effectiveness outcome
The primary outcome is pain experienced over the first
5 postoperative days, as assessed using a VRS, captured
three times a day.
Secondary effectiveness outcomes
The following will be captured as secondary outcomes: pain
control assessed by the Overall Benefit of Analgesia Score
(OBAS) [31] preoperatively and once daily postoperatively
for 5 days; pain assessed by the Self-completed Leeds As-
sessment of Neuropathic Symptoms and Signs (S-LANSS)
[32] preoperatively and on postoperative day 5; and opioid
use measured preoperatively and once daily postoperatively
for 5 days, converted to morphine equivalents. Pain, as
assessed by the S-LANSS and the Groningen PLP ques-
tionnaire, will be captured at 6-week and 6- month follow
up. QoL will be assessed preoperatively and at 2-month
and 6-month follow up using the Euroquol-5D-5 L health
questionnaire (EQ-5D-5 L) and Hospital Anxiety and De-
pression Scale (HADS). Surgical-site infection rates, classi-
fied as per the 2008 Centers for Disease Control/National
Healthcare Safety Network (CDC/NHSN) document, will
be recorded. We will also capture the rate of successful
identification of the nerve and PNC placement, and re-
source usage during the first 6 postoperative months.
Study procedures
Site selection and training
This study will be carried out at two tertiary vascular
surgery hospital sites in Wales; the Royal Gwent Hos-
pital, Aneurin Bevan University Health Board and Mor-
riston Hospital, Abertawe Bro Morgannwg University
Health Board. Full contact details of the recruitment
centres can be found in the ISRCTN registration.
Registration and consent
The study plan and patient flow are shown in Fig. 1.
Patients listed for major lower limb amputation will be
screened by members of the clinical care team against the
inclusion/exclusion criteria. Potentially suitable patients
will be approached, provided with all necessary informa-
tion Additional file 2, and if appropriate will be consented
by a medically trained member of the study team
Additional file 3. Patients undergoing emergency surgery
will only be approached if their clinical condition allows
sufficient time to obtain adequate informed consent. An
anonymous screening log of all patients undergoing major
lower limb amputation but not enrolled will be main-
tained at both sites to measure potential selection bias.
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Randomisation
Patients will be randomised intra-operatively (preferably)
or preoperatively (if logistically required). Patients will
be randomised in a 1:1 ratio to either active treatment
(placement of a PNC with a postoperative infusion of
0.125% levobupivacaine in addition to standard anaes-
thetic and postoperative analgesia) or control (standard
anaesthetic and postoperative analgesia alone). Compu-
terised web-based remote randomisation (available
24 hours a day) will be used, with telephone backup
during working hours. Randomisation will be minimised
according to level of amputation (BKA vs. AKA) and
sex, and stratified by site. The feasibility of concealing al-
location from for the surgical and anaesthetic team up
until the point at which the nerve is identified intraoper-
atively will be explored. This will be done by providing
the facility for either intraoperative randomisation, or for
randomisation to be performed preoperatively by an in-
dividual distinct from the surgical and anaesthetic team,
with the allocation left in a sealed envelope and opened
when the nerve is identified.
Criteria for crossover or withdrawal
Removal of the PNC and/or discontinuation of the local
anaesthetic infusion in the intervention arm will be
performed if the patient experiences an adverse drug re-
action or local site reaction or infection. Postoperative
placement of a percutaneous (radiologically guided)
PNC in the control arm is permitted at the discretion of
the treating clinician. Data collection will continue
without modification in the case of patient crossover,
but the crossover event will be recorded. Participants
may withdraw from the study at any point, without giv-
ing reasons. If reasons are given, these will be recorded
and reported. Permission will be sought from partici-
pants who withdraw to allow data that has already been
collected to be used in analysis.
Fig. 1 Trial schema and participant flow diagram
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Data collection
Preoperative and postoperative data will capture pain,
opioid use, nausea and vomiting, and other key mea-
sures. Follow-up assessments will be carried out either
by telephone or in person at approximately 2 and
6 months. The schedule of enrolment, interventions and
assessments is shown in line with the SPIRIT 2013 rec-
ommendations in Fig. 2 [24]. Participants completing
follow-up assessments will be given incentive vouchers
to encourage them to engage with follow up. Pain (both
PLP and CSP), analgesic use, complications, QoL and
healthcare costs will be assessed. Data will be coded,
stored and analysed at the Centre for Trials Research. It
will be recorded in a web-based database, which is a
secure encrypted system accessed by an institutional
password, and complies with UK Data Protection Act
standards. The primary outcome will be recorded using
the well-validated 11-point (0–10) VRS when captured
by study personnel. However, it became clear during the
design of the study that it would be difficult to record
this more than once each day, as research-trained
personnel were not regularly available first thing in the
morning, in the evening, or at the weekend. Daily pain
scores will therefore also be supplemented by the
simpler 0–3 scale (none, mild, moderate, severe), which
is recorded routinely by regular nursing staff on the
bedside observations chart.
Qualitative interviews and core outcome sets
In tandem with this research we are undertaking
complimentary qualitative work. Semi-structured, face-
to-face interviews will be conducted with patients
purposefully sampled to achieve variation in centre and
study arm. The target sample size is 10, dependent on sat-
uration of analytic themes on preliminary coding and dis-
cussion within the research team. The topic guide will be
developed in discussion with the multi-disciplinary study
team, including lay members, and reviewed and refined
throughout the interview process where necessary
Additional files 4 and 5. Patients will be interviewed
within the immediate postoperative period (expected to
be 1–4 weeks after amputation) and again at further fol-
low up (6–9 months after amputation). Interview 1 will
explore perceptions of pain including acute postoperative
pain and chronic stump pain, general illness experience
and the hospital stay, personal experiences of opioid use,
Fig. 2 Schedule of enrolment, interventions, and assessments. *Allocation may be done preoperatively or intra-operatively. If allocation is preoperative,
attempts will be made to conceal allocation from the surgical and anaesthetic teams up until the point where the nerve is identified, subject
to availability of study staff. VRS, verbal rating scale; S-LANSS, Self-completed Leeds Assessment of Neuropathic Symptoms and Signs; OBAS,
Overall Benefit of Analgesia Scale; PLP, phantom limb pain; QoL, quality of life; EQ-5D-5 L, EuroQol health questionnaire; SAE, serious adverse
event; SAR, serious adverse reaction; CRF, case report form
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and any other concerns. Interview 2 will explore general
illness experience including physical and psychological,
experience of long term pain (including PLP), current pain
relief, recovery, and rehabilitation. Interviews will also ex-
plore patients’ experiences of study processes. Interviews
will be audio-recorded, transcribed verbatim, and anon-
ymised. The data will be managed using qualitative coding
software (NVivo 11). Thematic analysis will be used to
identify, analyse and report patterns within the data [33].
Themes will be identified that relate to research objectives,
but analysis will also allow new, unpredicted themes to be
identified that interviewees generate themselves. Data will
be double-coded (around 10–20%) and discrepancies dis-
cussed until consensus is reached and codes will be re-
fined if necessary.
Semi-structured interviews (telephone or face-to-face)
will be conducted with a total of 5–10 health profes-
sionals sampled from both sites involved in delivery of
the study Additional files 6 and 7. Interviews will explore
how delivery of the intervention was achieved and what
was delivered, how the intervention components and de-
livery processes worked in the real healthcare setting,
and acceptability of the study to patients and interven-
tion deliverers. We also plan the parallel development of
core outcome sets for amputation research, which is de-
scribed in detail elsewhere [26]. Patients who agree to
participate in these ancillary studies will be given add-
itional information about them and asked to sign add-
itional consent forms.
Analysis
Sample size
This study is focussed on feasibility and is not powered
to analyse effectiveness. A sample size of 50 participants
has been chosen to demonstrate this, which will allow
for feasibility outcomes to be conservatively estimated
with a 95% CI of ± 13.9 percentage points.
Statistical analysis
Analysis will be undertaken as per the full statistical
analysis plan, which will be implemented after data
collection is complete, and to which the analyst will be
blinded. The following feasibility outcomes will be exam-
ined: the proportion of eligible participants who consent
to the study; the proportion of patients who supply
primary outcome data; and the proportion of patients
reaching follow up, to evaluate PLP and CSP.
The primary effectiveness outcome of pain will be ana-
lysed using the average (mean) pain rating on the 11-point
VRS across the 5 days post-surgery. Simple linear regres-
sion will be used to estimate the treatment effect control-
ling for amputation type and other key demographics (e.g.
age, sex, recruiting site, pre-amputation pain score, anaes-
thetic type, use of percutaneous nerve blocks/catheters)
and the results summarised using regression coefficients,
95% CIs and effect sizes. Secondary analysis of the primary
outcome will explore the use of the maximum pain score
recorded and the area under the curve, and will also in-
clude information on total opioid use during the 5 days. If
there are missing data issues with the 11-point VRS,
defined as less than 90% of patients having at least one
11-point VRS recorded on each of the 5 postoperative
days, we will fall back on the 4-point scores, with 11 point
scores where available converted to 4-point values using a
validated algorithm [34]. The mode of the recorded values
will be used and an ordinal regression model used for ana-
lysis. Treatment failure, defined as a patient reaching a
pain score of 4 or more on the 11-point VRS, (moderate
or severe on the 4-point VRS) will also be compared
between arms using logistic regression, albeit no formal
hypothesis testing will be conducted.
Secondary effectiveness outcomes will be similarly
analysed. Continuous outcomes will be explored using
linear regression (standard transformations to improve
model fit will be used if indicated) and summarised
using regression coefficients with 95% CIs. Logistic re-
gression will be used for dichotomous outcomes and
summarised using odds ratios with 95% CIs. Secondary
outcomes include: the Overall Benefit of Analgesia Scale
(OBAS) score, the S-LANSS score at 5-day follow up,
QoL (EQ-5D-5 L), surgical infection rates (yes/no),
length of stay and 30-day mortality. All effectiveness
outcomes will be analysed in as-randomised groups.
Missing data will be addressed by using complete case
analysis. If this excludes more than 20% of participants we
will employ multiple imputation and report the impact on
the treatment effect alongside the complete case analysis.
Progression criteria
Progression to an RCT will occur after a complete re-
view of all components of the described pilot study
against the ACCEPT criteria [25]. This evaluates all
components of the trial including trial design, interven-
tion, the consent process, randomisation, blinding, data
management and analysis, research governance, and trial
management.
The following criteria are required for progression to
an RCT. The observed effect must not exclude a clinic-
ally significant benefit to patients in the treatment (i.e.
PNC) arm and the Trial Steering Committee (TSC) and
Trial Management Group (TMG) must approve the
study as safe, without excessive complications in either
study arm. For two further feasibility criteria, we will
employ a “traffic light” system to identify criteria levels
that we deem acceptable (green), possibly acceptable
with discussion and amendments (amber) and unaccept-
able (red). The first of these criteria is that the percent-
age of eligible patients that are randomised must be
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greater than 50% (green), or 25–50% (amber), with less
than 25% recruitment being a red light. Second, the
percentage of randomised patients that provide data for
the primary outcome must be greater than 90% (green),
or 60–90% (amber), with less than 60% primary outcome
data being a red light. The reasons for any amber lights
will be scrutinised, paying particular attention to rates of
those who meet an intra-operative exclusion criterion
and who would otherwise have been randomised, and
amendments to study procedures will be necessary
before a decision to proceed to an effectiveness trial can
be made.
We will also carry out a thorough process evaluation
to identify and address problems that might undermine
the successful delivery of the intervention in a full effect-
iveness trial [35]. Should we progress to a full RCT, data
from this pilot may be analysed in conjunction with data
captured in that trial, using a Bayesian approach. The
decision will be made after taking advice from the TSC,
and will depend primarily on the methodological similar-
ities between the two studies.
Ethical and governance approval
The full trial protocol was reviewed and approved by
Wales Research Ethics Committee (REC) 3, recognised
by the United Kingdom Ethics Committee Authority. All
hospital sites received Research and Development (R&D)
approval from the respective Health Boards in Wales. A
notice of no objection to the clinical trial notification
was obtained from the Medicines and Healthcare prod-
ucts Regulatory Agency (MHRA). The REC, Sponsor
and Health Boards’ R&D departments will be notified of
minor protocol revisions. Major protocol revisions will
be presented to the REC and the MHRA if appropriate,
and once approved, to the Sponsor and Health Boards’
R&D departments before implementation.
Management and safety
All key processes will be undertaken according to Cardiff
University Centre for Trials Research (CTR) Standard
Operating Procedures. Regular (monthly) TMG meet-
ings, including patient and public representatives, will
occur during the course of the study. Adverse events
and protocol deviations will be monitored by the CTR
and reported as required to the TSC who will meet regu-
larly to monitor progress. The TSC will act as the Data
Safety Monitoring Board. Given the small size and
nature of the study, it was decided by the TSC that no
formal interim analysis would be performed. No formal
stopping criteria have been drafted, although the TSC
have the ability to stop the study if there are safety con-
cerns. The study is coordinated by the CTR, who will
monitor and audit study procedures. Monitoring will be
conducted independently by a qualified member of CTR
staff not participating in the day-to-day study activities
at the research site.
Publication and dissemination of results
All publications and presentations relating to the study
will be authorised by the TMG and will be in accordance
with the study’s publication policy. In addition to the re-
quired final report and monograph for the funding body,
we will publish the main study results in international
open access peer-reviewed journals and present them at
national and international scientific meetings. With the
assistance of our collaborators and lay representatives
we will disseminate the study findings to a wide audi-
ence and vigorously promote uptake of the study results
into clinical care. This will include presentations at
meetings and written executive summaries for key stake-
holder groups such as Secondary Care Trusts, Royal Col-
leges, Medical Schools, and relevant patient groups.
Access to the full protocol, anonymised participant-level
data, and statistical code will be available from the study
team upon request after the main study results have
been published.
Discussion
PLACEMENT is designed to explore the feasibility of
running an effectiveness trial to assess the impact of a
perineural catheter (PNC) with continuous local anaes-
thetic infusion, inserted at the time of amputation, on
immediate and mid-term postoperative outcomes. If
feasible, an effectiveness trial will address the important
evidence gap in postoperative pain relief for amputees.
This is an important research priority, highlighted by the
recent NCEPOD report [4].
The primary effectiveness outcome was chosen follow-
ing input from a patient-engagement event with prior
amputees, organised during study set-up. The individ-
uals present felt that acute pain in the postoperative
period was an important issue. The measures chosen (an
11-point VRS with a back-up of the simpler 4-point VRS
recorded on the routine nursing observations chart)
reflect those recommended by consensus documents
and expert opinion [34, 36].
During the development of this study we decided
against a placebo control arm (i.e. insertion of a PNC
with an infusion of 0.9% saline), despite the potential for
introducing bias, for a number of reasons. First, we
wanted to design a pragmatic study that would compare
two “real life” treatments, which would be easily applic-
able to surgeons’ daily practice. Second, the placement
of a PNC comes with a theoretical risk of damaging the
nerve, which could in theory increase pain. Whilst there
are no reports of this occurring within the published lit-
erature as identified in our systematic review, we felt
that we needed to show whether the placement of a
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PNC was detrimental. Third, it is possible that infusion
of any inert fluid, such as 0.9% saline, would dilute
inflammatory mediators in the vicinity of the nerve and
thereby reduce pain, potentially resulting in the placebo
group experiencing pain relief despite no “active” infu-
sion. Finally, PNC placement may theoretically be asso-
ciated with an increase in surgical-site infection or other
complications, which would not be identified in a
placebo study. As the main focus for the present study
was feasibility, we decided against the need for a placebo
arm. If the feasibility outcomes of the study are achieved,
this topic will be re-visited in the planning phase of an
effectiveness trial.
During the design of this study we identified two similar
studies of note. The first, currently unreported, has been
undertaken in Leicester, recruiting 81 patients to receive a
PNC with either local anaesthetic or 0.9% saline. The sec-
ond is the FinAPain-1 study (ISRCTN45530042), a multi-
centre double-blind Finnish RCT of 180 patients
undergoing AKA for PAD [37]. Two catheters are placed
at the time of surgery; one PNC in the perineural space
and one PWC under the amputation wound. The inter-
vention group receives ropivacaine for 72 hours whilst the
control group receives 0.9% saline. Primary outcomes are
pain on postoperative days 1–5, and secondary outcomes
are postoperative opioid consumption, long-term PLP and
CSP, and adverse events. Recruitment is expected to be
complete by the end of 2017. PLACEMENT differs in that
only a PNC is used, the control arm has no PNC, both
AKAs and BKAs would be included, and levobupivacaine,
the most commonly used local anaesthetic as identified by
our systematic review, would be examined.
The PLACEMENT study will provide invaluable infor-
mation on the feasibility of evaluating the role of PNCs
in amputees in a full RCT. The study will facilitate a full
evaluation of all aspects of the trial, including site set-
up, training, recruitment and consent, logistical manage-
ment, procedural technique, immediate data collection,
and longer-term data capture. Qualitative interviews of
patients, surgical and medical staff will identify both
positive study aspects and aspects to be improved upon.
Data provided from the study will clarify issues around
the best primary outcome and facilitate a more accurate
sample size calculation. This will provide a strong foun-
dation upon which a future RCT can be based.
Trial status
The study is currently in the recruitment phase.
Additional files
Additional file 1: Spirit Checklist. (DOC 121 kb)
Additional file 2: PLACEMENT patient information sheet (DOCX 827 kb)
Additional file 3: PLACEMENT consent form (DOCX 1477 kb)
Additional file 4: Qualitative interview information sheet, healthcare
professional (DOCX 1470 kb)
Additional file 5: Qualitative interview information sheets, patient
(DOCX 416 kb)
Additional file 6: Qualitative interview consent form, healthcare
professional (DOCX 416 kb)
Additional file 7: Qualitative interview consent form, patient (DOCX
1469 kb)
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